MS4A6A

MS4A6A is a tetraspan membrane protein expressed predominantly in microglia and mast cells that modulates innate immune receptor trafficking and inflammatory signaling. In microglia, MS4A6A forms a complex with the co-receptor DAP12 to restrain TREM2 surface localization and signaling, with its own stability maintained through interaction with MS4A4A (PMID:41435829); loss of MS4A6A impairs microglial phagocytosis of amyloid plaques and disinhibits NF-κB signaling, exacerbating neuroinflammation and plaque pathology (PMID:40877951). In human mast cells, MS4A6A compensates for FcεRIβ by trafficking the FcεRI receptor complex to the cell surface to enable IgE-mediated degranulation (PMID:36424895). In endothelial cells, MS4A6A activates the IKK/NF-κB pathway to promote inflammatory cytokine production, adhesion molecule expression, and monocyte adhesion (PMID:40090082).

1. 2017 Medium

   Establishing how Alzheimer's-associated genetic variation at the MS4A locus controls MS4A6A expression: a risk SNP creates an antioxidant response element that recruits NRF1/NRF2 under proteostatic stress, providing a transcriptional mechanism linking GWAS signals to altered MS4A6A levels.

   Evidence Reporter assays with SNP site mutagenesis and NRF1/NRF2 manipulation under proteostatic stress

   PMID:29179108

   Open questions at the time

   • Whether NRF1-driven upregulation occurs in microglia specifically, rather than heterologous cell lines
   • Whether increased MS4A6A expression from this allele alters microglial function in vivo
2. 2019 Low

   GWAS of CSF soluble TREM2 levels identified MS4A6A variant rs7232 as genome-wide significant, and co-expression analysis in brain linked MS4A6A to TREM2 regulation — providing the first molecular phenotype connecting MS4A6A to TREM2 biology, though without a direct mechanistic test.

   Evidence GWAS of CSF sTREM2 in ADNI cohort with replication in independent Chinese cohort; brain co-expression analysis

   PMID:31204042

   Open questions at the time

   • Purely genetic association without direct biochemical validation of how MS4A6A controls sTREM2
   • Direction of causality not established
   • No cell-type-resolved mechanism
3. 2022 Medium

   Demonstrating a non-CNS function: MS4A6A traffics FcεRI complexes to the mast cell surface and enables IgE-mediated degranulation, acting as a compensatory FcεRIβ-like protein — establishing MS4A6A as a receptor trafficking chaperone in innate immunity.

   Evidence Exon-skipping oligonucleotides targeting FcεRIβ combined with degranulation assays in human mast cells

   PMID:36424895

   Open questions at the time

   • Whether MS4A6A directly binds FcεRIα or acts indirectly through lipid raft organization
   • Not tested whether this function extends to other MS4A family members
4. 2024 Low

   Identifying MS4A6A as a microglial-specific factor in the glioblastoma microenvironment whose overexpression promotes tumor cell proliferation and migration — extending its functional repertoire to tumor-associated microglia.

   Evidence scRNA-seq localization to microglia in glioblastoma tissue; in vitro overexpression with tumor cell proliferation/migration assays

   PMID:38488530

   Open questions at the time

   • No pathway or receptor target identified for the pro-tumorigenic effect
   • Gain-of-function only, no loss-of-function validation
   • In vivo tumor model not tested
5. 2025 High

   Resolving the biochemical mechanism by which MS4A6A controls TREM2: MS4A6A forms a complex with DAP12 that blocks TREM2 surface expression and signaling, while MS4A4A stabilizes MS4A6A protein, creating a druggable axis — antibody-mediated degradation of MS4A4A destabilizes MS4A6A and boosts TREM2.

   Evidence Reciprocal co-immunoprecipitation, CRISPR KO, MS4A4A-degrading antibodies in primary human microglia, non-human primates, and APP/PS1 amyloid mouse model

   PMID:41435829

   Open questions at the time

   • Structural basis for MS4A6A–DAP12 interaction not resolved
   • Whether MS4A6A also sequesters other ITAM-bearing adaptors beyond DAP12
6. 2025 High

   Demonstrating in vivo consequences: MS4A6A deficiency in amyloid mice impairs microglial plaque phagocytosis and decompacts plaques while disinhibiting NF-κB, establishing MS4A6A as a dual-function regulator that promotes phagocytosis yet restrains neuroinflammation.

   Evidence Ms4a6d-knockout APP/PS1 mice with high-resolution imaging, behavioral analysis, and transcriptomic validation via overexpression in human microglia

   PMID:40877951

   Open questions at the time

   • Paradox between MS4A6A restraining TREM2 signaling via DAP12 yet being required for phagocytosis is not fully reconciled
   • Whether NF-κB disinhibition is a direct consequence of lost MS4A6A or secondary to altered TREM2/DAP12 dynamics
7. 2025 Medium

   MS4A6A activates IKK/NF-κB signaling in ox-LDL-stimulated endothelial cells to drive inflammatory cytokine release and monocyte adhesion, extending its NF-κB regulatory role beyond microglia to vascular inflammation.

   Evidence siRNA knockdown in HUVECs with IKK inhibitor and IKK siRNA rescue; ApoE-knockout mouse model with high-cholesterol diet

   PMID:40090082

   Open questions at the time

   • Direction of NF-κB regulation is opposite to microglia (activating here vs. suppressive in microglia), with no reconciliation
   • Direct molecular target linking MS4A6A to IKK activation not identified
8. 2025 Medium

   CRISPRi knockdown in hiPSC-derived microglia showed MS4A6A loss increases ROS production and shifts microglia away from the disease-associated microglia (DAM) state toward an inflammatory state upon viral mimic stimulation — providing functional genomics confirmation that MS4A6A shapes microglial state transitions. (preprint)

   Evidence CRISPRi screens with ROS readout and CROP-seq single-cell transcriptomics in hiPSC-microglia (preprint)

   Open questions at the time

   • Preprint not yet peer-reviewed
   • Whether the DAM-promoting role of MS4A6A is TREM2/DAP12-dependent or operates through an independent pathway

• The apparent context-dependent directionality of MS4A6A's NF-κB regulation — suppressive in microglia but activating in endothelial cells — and whether its dual roles as a DAP12 sequesterer and phagocytosis promoter operate through the same or distinct molecular mechanisms remain unresolved.
• No structural data for MS4A6A or its complexes with DAP12 or MS4A4A
• Cell-type-specific signaling partners that explain opposing NF-κB phenotypes are unknown
• Whether MS4A6A modulates additional ITAM-bearing adaptors beyond DAP12 has not been tested